GlaxoSmithKline announces board and committee changes

GlaxoSmithKline has confirmed a series of changes to its board and committee structures, with various people taking on new roles.

It has been announced that Sir Robert Wilson has agreed to stand for re-election for one additional year at the company's annual general meeting in May 2013, reversing his previous decision to step down.

Sir Christopher Gent, chairman of GlaxoSmithKline, said: "I am pleased that Sir Robert has agreed to remain on the board for a further year to contribute his advice and guidance, as we continue the process of board renewal."

Meanwhile, Larry Culp will stand down from the board on September 30th 2012 following nine years service, instead of departing in May 2013 as originally planned.

Tom de Swaan and Professor Sir Roy Anderson will join the nomination committee, Lynn Elsenhans is to become part of the corporate responsibility committee and Jing Ulrich is joining the audit and risk committee, while Judy Lewent and Dr Stephanie Burns will take up roles on the remuneration committee.

GlaxoSmithKline is currently undergoing restructuring following the completion of its takeover of Human Genome Sciences in August 2012.